Markets

OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share

Jul 28, 2026 · 07:08 AM ET· updated 3h ago

OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

Why It Matters

A top scientist at OKYO Pharma bought some shares of the company at $1.49 each. When leaders buy their own company's stock, it can mean they believe in what the company is doing.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OKYO1.61

-0.03 (-2.13%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.